These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date and reported results 2014-000667-40 A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension Az APD811 – egy orálisan alkalm... 2017-06-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-003042-27 An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension Az APD811-003 vizsgálat nyílt kiterjesztett vizsgálata pulmonális artériás hipertóniában szenvedő betege... 2021-03-29 bad-data
Reported results 2015-001942-28 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely Active Ulcerative C... 2018-02-15 due-trials
Reported results 2015-002109-12 An Extension Study of APD334-003 in Patients with Moderately to Severely Active Ulcerative Colitis 2018-11-01 due-trials
Reported results 2016-003797-40 A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients with active Skin Extra-intestinal Manifestations 2017-10-02 due-trials
Ongoing 2018-001187-33 A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients not-yet-due
Ongoing 2018-001189-40 A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION not-yet-due
Listed as ongoing, but also has a completion date and reported results 2018-003985-15 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis 2022-02-16 bad-data
Listed as ongoing, but also has a completion date and reported results 2018-003986-33 A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis 2022-02-01 bad-data
Ongoing 2018-003987-29 An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis not-yet-due
Listed as ongoing, but also has a completion date and reported results 2019-002895-14 A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Seve... 2021-03-23 bad-data
Reported results Terminated 2020-000238-16 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutaneous... 2022-08-23 due-trials
Reported results 2020-003226-23 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis 2023-06-30 due-trials
Listed as ongoing, but also has a completion date 2020-003507-34 A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately Active Ulcerative Colitis 2024-06-19 bad-data
Ongoing 2020-004775-40 A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease not-yet-due
Reported results 2020-006131-10 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of APD418 in Subjects with Heart Failure with R... 2022-09-10 due-trials